arritmias ignacio fernández lozano. javier alzueta
DESCRIPTION
ARRITMIAS Ignacio Fernández Lozano. Javier Alzueta. FA. 402 PT. 1.376 PT. 5.700 PT CHADS FAPx 1,8 FAPn 2. 627 PT. 4.628 PT. - PowerPoint PPT PresentationTRANSCRIPT
ARRITMIAS Ignacio Fernández Lozano.Javier Alzueta.
FA
402 PT
1.376 PT
5.700 PT
CHADSFAPx 1,8FAPn 2
627 PT
End point Placebo (%/y)
Dronedarone (%/y)
HR (95% CI) p
Stroke 1.79 1.19 0.66 (0.46-0.96)
0.027
Stroke or TIA 2.05 1.37 0.67 (0.47-0.94)
0.020
Fatal stroke 0.54 0.36 0.67 (0.34-1.32)
0.247
Stroke, ACS, or CV death 5.52 3.80 0.68 (0.55-0.84)
<0.001
Stroke, ACS, or all-cause death 6.70 5.06 0.75 (0.62-0.90)
0.002
4.628 PT
Purpose The objective of this study is to compare the efficacy and safety of dronedarone to that of amiodarone for the treatment of patients with atrial fibrillation.
Arms Assigned Interventions
1: Experimental Drug: dronedarone (SR33589) 400mg bid
2: Active Comparator Drug: amiodarone 600mg daily for 28 days, then 200mg daily
Ages Eligible for Study: 21 Years and olderGenders Eligible for Study: BothAccepts Healthy Volunteers: No
504 PT
112 PT
SINCOPE
Estratificación de riesgo
504 PT
Incidencia de Muerte súbitaMyerburg RJ. Circulation.1998;97:1514-1521.
GROUP
>2 factores de riesgo
Pacientes con enfermedad coronaria
Pacientes con FE <35%,
e ICCPacientes con PCR previa
Pacientes con IAM FE deprimida y TV
Población global
300,000200,000100,0000
Nº. De MS anual
3025201050
Incidencia de MS(% grupo)
High energy implant rates pmp
Avg = 160
Avg = 133
USAGermany
ItalyNetherlands
IrelandWestern Europe
DenmarkAustria
SwitzerlandBelgiumFrance
UKFinland
SwedenNorway
SpainPortugal
0 100 200 300 400 500 600 700
ICD CRT-D 2006 WE Average 2005 WE Average
Source: Eucomed
490 PT
651 PT
206 PT
45 PT
7.001 PT